187 related articles for article (PubMed ID: 30922689)
21. Re: Börje Ljungberg, Laurence Albiges, Yasmin Abu-Ghanem, et al. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.03.006.
Wei Y; Zhang R; Lin L
Eur Urol; 2022 Sep; 82(3):e88. PubMed ID: 35750581
[No Abstract] [Full Text] [Related]
22. Reply to Takeshi Takahashi's Letter to the Editor re: Bimal Bhindi, Christine M. Lohse, Phillip J. Schulte, et al. Predicting functional outcomes after partial and radical nephrectomy. Eur Urol 2019;75:766-72. Partial Nephrectomy: "Geocentrism" of the 21st century in the Church of Urology?
Bhindi B; Lohse CM; Schulte PJ; Mason RJ; Cheville JC; Boorjian SA; Leibovich BC; Thompson RH
Eur Urol; 2019 Sep; 76(3):e67-e68. PubMed ID: 31167750
[No Abstract] [Full Text] [Related]
23. Re: Jack R. Andrews, Thomas Atwell, Grant Schmit, et al. Oncologic Outcomes Following Partial Nephrectomy and Percutaneous Ablation for cT1 Renal Masses. Eur Urol 2019;76:244-51.
Pecoraro A; Porpiglia F; Karakiewicz PI
Eur Urol; 2020 Mar; 77(3):e74. PubMed ID: 31607394
[No Abstract] [Full Text] [Related]
24. Reply to Homayoun Zargar, Rafael F. Coelho and Jihad H. Kaouk's Letter to the Editor re: R. Houston Thompson, Tom Atwell, Grant Schmit, et al. Comparison of Partial Nephrectomy and Percutaneous Ablation for cT1 Renal Masses. Eur Urol 2015;67:252-9.
Thompson RH; Atwell T; Schmit G; Lohse CM; Kurup AN; Weisbrod A; Psutka SP; Stewart SB; Callstrom MR; Cheville JC; Boorjian SA; Leibovich BC
Eur Urol; 2015 Feb; 67(2):e24-5. PubMed ID: 25257032
[No Abstract] [Full Text] [Related]
25. Re: Steiner T, Knels R, Schubert J. Prognostic significance of tumor size in patients after tumour nephrectomy for localised renal cell carcinoma. Eur Urol 46;2004:327-30.
Bogdanovic J
Eur Urol; 2005 Feb; 47(2):266-7. PubMed ID: 15661427
[No Abstract] [Full Text] [Related]
26. Re: Partial nephrectomy in the setting of metastatic renal cell carcinoma: K. N. Babaian, M. M. Merrill, S. Matin, P. Tamboli, N. M. Tannir, E. Jonasch, C. G. Wood and J. A. Karam J Urol 2014; 192: 36-42.
Giri V; Jha AK; Yadav SS
J Urol; 2015 Feb; 193(2):733; discussion 733-4. PubMed ID: 25445577
[No Abstract] [Full Text] [Related]
27. Partial nephrectomy is not associated with an overall survival advantage over radical nephrectomy in elderly patients with stage Ib-II renal masses: An analysis of the national cancer data base.
Ristau BT; Handorf EA; Cahn DB; Kutikov A; Uzzo RG; Smaldone MC
Cancer; 2018 Oct; 124(19):3839-3848. PubMed ID: 30207380
[TBL] [Abstract][Full Text] [Related]
28. Re: Bimal Bhindi, E. Jason Abel, Laurence Albiges, et al. Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma. Eur Urol 2019;75:111-28: Cytoreductive Nephrectomy in the Targeted Therapy Era: This is Not the End.
Massari F; Di Nunno V; Santoni M; Gatto L; Mollica V; Porta C
Eur Urol Oncol; 2019 Sep; 2(5):603-604. PubMed ID: 31411982
[No Abstract] [Full Text] [Related]
29. Re: Outcomes following partial nephrectomy by tumor size P. L. Crispen, S. A. Boorjian, C. M. Lohse, T. S. Sebo, J. C. Cheville, M. L. Blute and B. C. Leibovich J Urol 2008; 180: 1912-1917.
Cimen HI; Serefoglu EC; Balbay MD
J Urol; 2009 Sep; 182(3):1232; author reply 1232. PubMed ID: 19625039
[No Abstract] [Full Text] [Related]
30. Re: Raj Satkunasivam, Sheaumei Tsai, Sumeet Syan, et al. Robotic Unclamped "Minimal-margin" Partial Nephrectomy: Ongoing Refinement of the Anatomic Zero-ischemia Concept. Eur Urol 2015;68:705-12.
Zu X; Qi L; Liu L
Eur Urol; 2016 Apr; 69(4):e72-e73. PubMed ID: 26489477
[No Abstract] [Full Text] [Related]
31. Re: Capitanio et al.: Cytoreductive partial nephrectomy does not undermine cancer control in metastatic renal cell carcinoma: a population-based study. (Urology 2008;72:1090-1095).
Chung SD; Chu SH; Tsai CC
Urology; 2009 Mar; 73(3):682-3; author reply 683-4. PubMed ID: 19248907
[No Abstract] [Full Text] [Related]
32. Survival after partial and radical nephrectomy for the treatment of stage T1bN0M0 renal cell carcinoma (RCC) in the USA: a propensity scoring approach.
Badalato GM; Kates M; Wisnivesky JP; Choudhury AR; McKiernan JM
BJU Int; 2012 May; 109(10):1457-62. PubMed ID: 21933334
[TBL] [Abstract][Full Text] [Related]
33. Cancer-specific and non-cancer-related mortality rates in European patients with T1a and T1b renal cell carcinoma.
Zini L; Patard JJ; Capitanio U; Crepel M; de La Taille A; Tostain J; Ficarra V; Bernhard JC; Ferrière JM; Pfister C; Villers A; Montorsi F; Karakiewicz PI
BJU Int; 2009 Apr; 103(7):894-8. PubMed ID: 19076131
[TBL] [Abstract][Full Text] [Related]
34. Re: outcome of stage T2 or greater renal cell cancer treated with partial nephrectomy: R. H. Breau, P. L. Crispen, R. E. Jimenez, C. M. Lohse, M. L. Blute and B. C. Leibovich J Urol 2010; 183: 903-908.
Cimen HI; Canda AE; Balbay MD
J Urol; 2010 Nov; 184(5):2212; author reply 2212-3. PubMed ID: 20864129
[No Abstract] [Full Text] [Related]
35. The Role of Cytoreductive Nephrectomy: European Association of Urology Recommendations in 2016.
Bex A; Ljungberg B; van Poppel H; Powles T;
Eur Urol; 2016 Dec; 70(6):901-905. PubMed ID: 27445002
[TBL] [Abstract][Full Text] [Related]
36. Can partial nephrectomy provide equal oncological efficiency and safety compared with radical nephrectomy in patients with renal cell carcinoma (≥4cm)? A propensity score-matched study.
Lee H; Oh JJ; Byun SS; Jeong CW; Kwak C; Jeong BC; Jeon SS; Lee HM; Choi HY; Seo SI
Urol Oncol; 2017 Jun; 35(6):379-385. PubMed ID: 28284894
[TBL] [Abstract][Full Text] [Related]
37. Re: Dawidek et al: Assessing Time of Full Renal Recovery Following Minimally Invasive Partial Nephrectomy (Urology 2018;112:98-102).
Cozzi DA; Ceccanti S; Cozzi F
Urology; 2018 Aug; 118():246-247. PubMed ID: 29777789
[No Abstract] [Full Text] [Related]
38. Rebuttal from authors re: Edward M. Messing. Node positive renal cell cancer. Who can be helped? Eur Urol 2007;51:1477-8.
Karakiewicz P; Perrotte P; Trinh QD; Patard JJ
Eur Urol; 2007 Jun; 51(6):1478-80. PubMed ID: 17275988
[No Abstract] [Full Text] [Related]
39. Re: Robert J. Motzer, Paul Russo, Naomi Haas, et al. Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients with Localized or Locally Advanced Renal Cell Carcinoma: Final Overall Survival Analysis of the Phase 3 PROTECT Trial. Eur Urol 2021;79:334-8: PROTECTing Patients with Locally Advanced Kidney Cancer.
Singla N; Pierorazio P; Allaf M; Ged Y
Eur Urol; 2021 Jul; 80(1):e33-e34. PubMed ID: 33962807
[No Abstract] [Full Text] [Related]
40. Similar functional outcomes after partial nephrectomy for clinical T1b and T1a renal cell carcinoma.
Iizuka J; Kondo T; Hashimoto Y; Kobayashi H; Ikezawa E; Takagi T; Omae K; Tanabe K
Int J Urol; 2012 Nov; 19(11):980-6. PubMed ID: 22735049
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
